Literature DB >> 26519672

Refined balloon pulmonary angioplasty driven by combined assessment of intra-arterial anatomy and physiology--Multimodal approach to treated lesions in patients with non-operable distal chronic thromboembolic pulmonary hypertension--Technique, safety and efficacy of 50 consecutive angioplasties.

Marek Roik1, Dominik Wretowski2, Andrzej Łabyk2, Maciej Kostrubiec2, Katarzyna Irzyk2, Olga Dzikowska-Diduch2, Barbara Lichodziejewska2, Michał Ciurzyński2, Katarzyna Kurnicka2, Marek Gołębiowski3, Piotr Pruszczyk2.   

Abstract

BACKGROUND/
OBJECTIVES: Balloon pulmonary angioplasty (BPA) is an emerging therapeutic method in CTEPH. We aimed to prove the safety and efficacy of refined BPA driven by combined assessment of intra-arterial anatomy (IVUS/OCT) and physiology (pulmonary pressure ratio, PPR) in non-operable distal CTEPH.
METHODS: 11 pts (mean age 76, 59–84, 7 males) were enrolled in the BPA program according to the following inclusion criteria: 1. Non-operable CTEPH; 2. RHC with mPAP > 30 mm Hg; 3. At least one segmental perfusion defect at lung scintigraphy; 4. WHO class > II. Overall, 9 pts underwent 27 BPA sessions (mean 3 sessions per patient, range 1–5), 50 pulmonary arteries were dilated (mean 6 vessels per patient, range 3–9; 2.03 dilated arteries per session). All the angioplasties were performed according to an algorithm, which incorporated anatomical and functional assessment of targeted lesions.
RESULTS: We performed BPA of 32 web lesions, 5 ring-like stenosis and 13 complete obstructions. BPA resulted in clinical and hemodynamic improvement. WHO class improved from pre-BPA to post-BPA (p = 0.018), and 6 MWD increased from 304 m to 384 m (p = 0.03), NT-proBNP dropped from 1248 pg/ml to 730 pg/ml (p < 0.001). Mean PAP and PVR decreased (p = 0.01), while CO and CI increased (p = 0.01). All dilated arteries were patent at angiographic reassessment. No significant complications occurred and all treated patients are still alive. Insignificant transient reperfusion pulmonary oedema occurred in only 2 patients, who responded well to supplemental oxygen.
CONCLUSIONS: Refined BPA with assessment of intrapulmonary physiology using a pressure wire and precise evaluation of anatomy with IVUS and OCT provides hemodynamic and functional improvement, with minimal complications in distal non-operable CTEPH. This observation requires further validation in a large prospective study.

Entities:  

Keywords:  Balloon pulmonary angioplasty; Chronic thromboembolic pulmonary hypertension; Efficacy; Multimodality (PPR/OCT/IVUS); Safety

Mesh:

Year:  2015        PMID: 26519672     DOI: 10.1016/j.ijcard.2015.10.116

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  11 in total

1.  Cardio-pulmonary MRI for detection of treatment response after a single BPA treatment session in CTEPH patients.

Authors:  Christian Schoenfeld; Jan B Hinrichs; Karen M Olsson; Martin-Alexander Kuettner; Julius Renne; Till Kaireit; Christoph Czerner; Frank Wacker; Marius M Hoeper; Bernhard C Meyer; Jens Vogel-Claussen
Journal:  Eur Radiol       Date:  2018-10-11       Impact factor: 5.315

2.  Chronic thromboembolic pulmonary hypertension: Evaluation of 2D-perfusion angiography in patients who undergo balloon pulmonary angioplasty.

Authors:  Sabine K Maschke; Julius Renne; Thomas Werncke; Karen M Olsson; Marius M Hoeper; Frank K Wacker; Bernhard C Meyer; Jan B Hinrichs
Journal:  Eur Radiol       Date:  2017-03-30       Impact factor: 5.315

3.  Hypertension: Surgery remains treatment of choice for CTEPH.

Authors:  Anton Vonk Noordegraaf; Harm J Bogaard
Journal:  Nat Rev Cardiol       Date:  2016-03-10       Impact factor: 32.419

Review 4.  Treatment of Chronic Thromboembolic Pulmonary Hypertension: The Role of Medical Therapy and Balloon Pulmonary Angioplasty.

Authors:  Timothy M Fernandes; David S Poch; William R Auger
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

5.  C-Arm computed tomography (CACT)-guided balloon pulmonary angioplasty (BPA): Evaluation of patient safety and peri- and post-procedural complications.

Authors:  Sabine K Maschke; Jan B Hinrichs; Julius Renne; Thomas Werncke; Hinrich M B Winther; Kristina I Ringe; Karen M Olsson; Marius M Hoeper; Frank K Wacker; Bernhard C Meyer
Journal:  Eur Radiol       Date:  2018-09-12       Impact factor: 5.315

Review 6.  Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.

Authors:  Amanda Lloji; Urvashi Hooda; Jayakumar Sreenivasan; Ramin Malekan; Wilbert S Aronow; Gregg M Lanier
Journal:  Am J Cardiovasc Dis       Date:  2021-06-15

7.  High prevalence of severe coronary artery disease in elderly patients with non-operable chronic thromboembolic pulmonary hypertension referred for balloon pulmonary angioplasty.

Authors:  Marek Roik; Dominik Wretowski; Maciej Kostrubiec; Olga Dzikowska-Diduch; Andrzej Łabyk; Katarzyna Irzyk; Barbara Lichodziejewska; Anna Wyzgał; Krzysztof Jankowski; Piotr Pruszczyk
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-11-17       Impact factor: 1.426

8.  Optical coherence tomography improves the results of balloon pulmonary angioplasty in inoperable chronic thrombo-embolic pulmonary hypertension.

Authors:  Aleksander Araszkiewicz; Stanisław Jankiewicz; Magdalena Łanocha; Magdalena Janus; Tatiana Mularek-Kubzdela; Maciej Lesiak
Journal:  Postepy Kardiol Interwencyjnej       Date:  2017-05-30       Impact factor: 1.426

9.  Balloon pulmonary angioplasty - efficient therapy of chronic thromboembolic pulmonary hypertension in the patient with advanced sarcoidosis - a case report.

Authors:  Andrzej Labyk; Dominik Wretowski; Sabina Zybińska-Oksiutowicz; Aleksandra Furdyna; Katarzyna Ciesielska; Dorota Piotrowska-Kownacka; Olga Dzikowska -Diduch; Barbara Lichodziejewska; Andrzej Biederman; Piotr Pruszczyk; Marek Roik
Journal:  BMC Pulm Med       Date:  2018-08-16       Impact factor: 3.317

10.  Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis.

Authors:  Wuwan Wang; Li Wen; Zhengdong Song; Wenhai Shi; Ke Wang; Wei Huang
Journal:  Clin Cardiol       Date:  2019-06-12       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.